News | January 10, 2025
Carbogen Amcis successfully completed Swissmedic inspection of its Vionnaz facility
The site’s GMP Certification has been successfully renewed
The site’s GMP Certification has been successfully renewed
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
The grant is designated for the research and development of Pyronaridine
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Subscribe To Our Newsletter & Stay Updated
